| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $14.1M | +128.2% |
| R&D Expense | $25.2M | -53.3% |
| SG&A Expense | $15.9M | -28.1% |
| Operating Income | -$38.2M | +50.0% |
| Income Tax | $0 | — |
| Net Income | -$33.5M | +52.1% |
| EPS (Basic) | -$0.17 | +55.3% |
| EPS (Diluted) | -$0.17 | +55.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $18.0M | -50.4% |
| Short-term Investments | $73.5M | -14.9% |
| Accounts Receivable | $1.4M | -39.9% |
| Current Assets | $94.5M | -25.8% |
| Total Assets | $94.6M | -28.2% |
| Current Liabilities | $6.0M | -61.5% |
| Long-term Debt | $0 | — |
| Total Liabilities |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$39.6M | +38.9% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $15.6M | -32.1% |
| Financing Cash Flow | $5.7M | -89.0% |
| Free Cash Flow | -$39.6M | +39.1% |
| $18.0M |
| -47.5% |
| Stockholders' Equity | $76.6M | -21.4% |